AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Statistics

Total Valuation

AmCad BioMed has a market cap or net worth of TWD 965.83 million. The enterprise value is 667.39 million.

Market Cap	965.83M
Enterprise Value	667.39M

Important Dates

The last earnings date was Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 17.23% in one year.

Current Share Class	63.33M
Shares Outstanding	63.33M
Shares Change (YoY)	+17.23%
Shares Change (QoQ)	+1.75%
Owned by Insiders (%)	6.60%
Owned by Institutions (%)	0.95%
Float	32.95M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.15
PB Ratio	1.56
P/TBV Ratio	2.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.84
EV / Sales	15.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.25

Financial Position

The company has a current ratio of 24.52, with a Debt / Equity ratio of 0.01.

Current Ratio	24.52
Quick Ratio	22.77
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.13
Interest Coverage	-554.28

Financial Efficiency

Return on equity (ROE) is -11.72% and return on invested capital (ROIC) is -8.50%.

Return on Equity (ROE)	-11.72%
Return on Assets (ROA)	-8.27%
Return on Invested Capital (ROIC)	-8.50%
Return on Capital Employed (ROCE)	-11.91%
Revenue Per Employee	1.28M
Profits Per Employee	-1.66M
Employee Count	34
Asset Turnover	0.08
Inventory Turnover	0.69

Taxes

Income Tax	-15,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.55% in the last 52 weeks. The beta is 0.31, so AmCad BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	-33.55%
50-Day Moving Average	15.47
200-Day Moving Average	17.77
Relative Strength Index (RSI)	53.12
Average Volume (20 Days)	93,253

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AmCad BioMed had revenue of TWD 43.60 million and -56.39 million in losses. Loss per share was -0.90.

Revenue	43.60M
Gross Profit	23.74M
Operating Income	-74.27M
Pretax Income	-62.80M
Net Income	-56.39M
EBITDA	-63.13M
EBIT	-74.27M
Loss Per Share	-0.90

Balance Sheet

The company has 392.93 million in cash and 7.19 million in debt, giving a net cash position of 385.75 million or 6.09 per share.

Cash & Cash Equivalents	392.93M
Total Debt	7.19M
Net Cash	385.75M
Net Cash Per Share	6.09
Equity (Book Value)	619.41M
Book Value Per Share	8.26
Working Capital	416.48M

Cash Flow

In the last 12 months, operating cash flow was -51.58 million and capital expenditures -2.89 million, giving a free cash flow of -54.47 million.

Operating Cash Flow	-51.58M
Capital Expenditures	-2.89M
Free Cash Flow	-54.47M
FCF Per Share	-0.86

Margins

Gross margin is 54.46%, with operating and profit margins of -170.37% and -129.34%.

Gross Margin	54.46%
Operating Margin	-170.37%
Pretax Margin	-144.05%
Profit Margin	-129.34%
EBITDA Margin	-144.80%
EBIT Margin	-170.37%
FCF Margin	n/a

Dividends & Yields

AmCad BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.23%
Shareholder Yield	n/a
Earnings Yield	-5.84%
FCF Yield	-5.64%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AmCad BioMed has an Altman Z-Score of 34.29 and a Piotroski F-Score of 2.

Altman Z-Score	34.29
Piotroski F-Score	2